A5082874897- Bone health and treatments
- Bone health and osteoporosis research
- Anesthesia and Pain Management
- Bone Metabolism and Diseases
- Nausea and vomiting management
- Bone and Joint Diseases
- Neurosurgical Procedures and Complications
- Cerebrospinal fluid and hydrocephalus
- Radiopharmaceutical Chemistry and Applications
- Enhanced Recovery After Surgery
- Neurological disorders and treatments
- Nerve Injury and Rehabilitation
- Platelet Disorders and Treatments
- Parkinson's Disease Mechanisms and Treatments
- Eosinophilic Disorders and Syndromes
- Pituitary Gland Disorders and Treatments
- Balance, Gait, and Falls Prevention
- Amoebic Infections and Treatments
- Spine and Intervertebral Disc Pathology
- Systemic Sclerosis and Related Diseases
- Abdominal Trauma and Injuries
- Glioma Diagnosis and Treatment
- Electroconvulsive Therapy Studies
- Airway Management and Intubation Techniques
- Cardiac, Anesthesia and Surgical Outcomes
Shizuoka General Hospital
2024
Hamamatsu University School of Medicine
2022
Nagoya City University
2022
Asahi Kasei (Japan)
2016-2021
Kushiro City General Hospital
1991-1997
Kagawa University
1992
In a 2-year randomized, placebo-controlled study of 665 Japanese patients with primary osteoporosis, once-yearly administration zoledronic acid (5 mg) reduced the risk new morphometric vertebral fractures. The purpose this was to determine efficacy and safety intravenous infusion ZOL in osteoporosis. This two-year multicenter, placebo-controlled, double-blind, parallel-group comparative (ZONE Study). Subjects were between ages 65 89 years who had prevalent fracture. randomly assigned receive...
Abstract In a clinical trial involving Japanese patients with osteoporosis, post hoc analyses were performed to evaluate the incidence of acute phase reactions (APRs) after infusion zoledronic acid (ZOL). The results highlighted differences in baseline factors between vs without APRs. Changes efficacy indicators such as bone turnover markers (BTMs) also showed significant differences. We, therefore, investigated involved development APRs treated once-yearly intravenous ZOL 5 mg for 2 years...
Abstract Background Mild cognitive impairment in Parkinson’s disease (PD-MCI) is associated with an increased risk of decline. PD-MCI characterized by impairments executive function and visuospatial recognition. The n-back test useful for assessing both domains. 0-back reflects recognition, while the 1-back 2-back tests reflect working memory. Cholinesterase inhibitors are effective treatment dementia PD (PDD). Although some studies have reported efficacy memantine PDD, therapeutic patients...
Abstract Objective: This randomized, clinical trial investigated whether zoledronic acid combined with oral health maintenance can improve periodontal disease associated osteoporosis, thus reducing the risk of tooth loss. Methods: Participants were those ZONE (ZOledroNate treatment in efficacy to osteoporosis) study. None participants had symptomatic at baseline. received either (5 mg; n = 333 [male 21, female 312]) or placebo (n 332 19, 313]) once yearly for 2 years, and their age was 74.0...
The effects of zoledronic acid on hip structural and biomechanical properties were evaluated in Japanese patients with osteoporosis by computed tomography (CT). subjects included this study a subset female (zoledronic group, 49 subjects; placebo 53 subjects) the phase 3 trial (ZONE study) who available for multi-detector row CT (MDCT) scanning. Eligible those diagnosed primary based Diagnostic Criteria Primary Osteoporosis (2000) Society Bone Mineral Research had between one four fractured...
Abstract Although changes in serum sclerostin levels at 12 months after infusion of zoledronic acid have been reported, the earlier time points are poorly understood. We reanalyzed study data a previous phase 1 pharmacokinetic and investigated correlation between relevant factors calcium metabolism. A total 24 Japanese female subjects with primary postmenopausal osteoporosis were administered single 4- or 5-mg dose acid. Serum urine samples collected on days 15, 29, 90, 180, 365...
Preoperative intravenous administration of high-dose γ-globulin and platelet transfusion have produced a satisfactory control operative postoperative hemorrhage in cholecystectomy for massive intracystic bleeding the gallbladder, 28-year-old male with aplastic anemia accompanied by severe thrombocytopenia (3, 000/μl) marked prolongation time (60 min), which has been known to be refractory transfusion. Gramma-globulin (10g/day) was administered intravenously three preoperative days...